Treatment of early-stage HER2+ breast cancer-an evolving field
about
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.Targeting Transcription Factors in CancerHexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma.The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.Research needs in breast cancer.
P2860
Treatment of early-stage HER2+ breast cancer-an evolving field
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Treatment of early-stage HER2+ breast cancer-an evolving field
@ast
Treatment of early-stage HER2+ breast cancer-an evolving field
@en
Treatment of early-stage HER2+ breast cancer-an evolving field
@nl
type
label
Treatment of early-stage HER2+ breast cancer-an evolving field
@ast
Treatment of early-stage HER2+ breast cancer-an evolving field
@en
Treatment of early-stage HER2+ breast cancer-an evolving field
@nl
prefLabel
Treatment of early-stage HER2+ breast cancer-an evolving field
@ast
Treatment of early-stage HER2+ breast cancer-an evolving field
@en
Treatment of early-stage HER2+ breast cancer-an evolving field
@nl
P2860
P3181
P356
P1476
Treatment of early-stage HER2+ breast cancer-an evolving field
@en
P2093
Kamal S Saini
Otto Metzger-Filho
P2860
P3181
P356
10.3332/ECANCER.2015.523
P407
P577
2015-04-16T00:00:00Z